|
Oct 1
|
PolyPid Announces Last Patient In for Planned Unblinded Interim Analysis in the Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections
|
|
Jul 31
|
PolyPid to Report Second Quarter 2024 Financial Results and Operational Highlights on August 14, 2024
|
|
Jun 18
|
PolyPid Hosts KOL Call to Discuss Significant Unmet Medical Need in Surgical Site Infections Prevention and Provides Update on its Ongoing SHIELD II Phase 3 Trial
|
|
May 10
|
PolyPid Ltd. (NASDAQ:PYPD) Q1 2024 Earnings Call Transcript
|
|
May 8
|
PolyPid Provides Corporate Update and Reports First Quarter 2024 Financial Results
|
|
May 1
|
PolyPid to Participate in Citizens JMP Life Sciences Conference
|
|
Apr 30
|
PolyPid Announces Enrollment of 200th Patient in Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections
|
|
Apr 24
|
PolyPid to Report First Quarter 2024 Financial Results and Operational Highlights on May 8, 2024
|
|
Apr 24
|
PYPD: Polypid is Enhancing Surgical Outcomes
|
|
Feb 19
|
PolyPid Ltd. (PYPD) Upgraded to Buy: What Does It Mean for the Stock?
|
|
Aug 9
|
PolyPid Provides Corporate Update and Reports Second Quarter 2023 Financial Results
|
|
Apr 26
|
PolyPid to Report First Quarter 2023 Financial Results and Operational Highlights on May 10, 2023
|
|
Apr 24
|
PolyPid to Participate in Upcoming Investor Conferences
|